Permira Partners with Marcucci Family, ADIA and Ampersand to Combine Kedrion and BPL

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

May 17, 2022

Healthcare Services

Alliance Pharma, an Ampersand-backed US bioanalytical CRO, acquired Drug Development Solutions (DDS), LGC’s UK-based bioanalytical and materials science testing business. Ampersand Capital Partners and KKR will be equal shareholders in the combined business to expand geographic reach, broaden laboratory capabilities, and extend the service portfolio internationally.

Permira Makes Substantial Growth Investment in PharmaCord

June 6, 2024

Healthcare Services

Permira (via a company backed by Permira funds) has signed a definitive agreement to make a substantial growth investment in PharmaCord, a Jeffersonville, Indiana-based tech-enabled patient services provider for specialty pharmaceuticals. Founder and CEO Nitin Sahney and the management team will remain significant investors and operators; terms were not disclosed and the deal is expected to close by Q4 2024.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Accord Plasma (Intas) Acquires Prothya Biosolutions

October 21, 2025

Pharmaceuticals

Accord Plasma, a subsidiary of Intas Pharmaceuticals, has completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. The deal adds Prothya’s European plasma fractionation facilities and collection network — including operations in Amsterdam, Brussels and Hungary — to Accord’s global plasma manufacturing footprint to expand production and access to plasma-derived medicines.

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.